Want to join the conversation?
Leading specialty pharmaceutical company, $PRGO today received an AB therapeutic equivalent rating & USFDA approval for BenzaClin, a topical gel treatment for acne vulgaris. Both generic & branded sales generated $231MM in revenue last year."This product approval & launch is an important addition to $PRGO's growing Rx portfolio," said Joseph, CEO.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.